



(12) Translation of
European patent specification

(11) NO/EP 2750717 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 51/08 (2006.01)
A61K 31/555 (2006.01)
A61K 38/08 (2019.01)
A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.09.16
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.03.27
(86)	European Application Nr.	12828526.9
(86)	European Filing Date	2012.08.23
(87)	The European Application's Publication Date	2014.07.09
(30)	Priority	2011.08.31, DK, 201100654 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Somscan ApS, Marielystvej 11, 2000 Frederiksberg, Danmark
(72)	Inventor	KJAER, Andreas, Marielystvej 11, DK-2000 Frederiksberg, Danmark KNIGGE, Ulrich, Blegdamsvej 9, DK-2100 København Ø, Danmark HØJGAARD, Liselotte, Blegdamsvej 9, DK-2100 København Ø, Danmark RASMUSSEN, Palle, Frederiksborgvej 399, DK-4000 Roskilde, Danmark
(74)	Agent or Attorney	Orsnes Patent ApS, Forskerparken 10, 5230 ODENSE, Danmark

(54)	Title	PET TRACER FOR IMAGING OF NEUROENDOCRINE TUMORS
(56)	References Cited:	US-A1- 2007 025 910 ZHANG H.: '64Cu-DOTA-Tyr3-c(Cys-Cyr-Trp-Lys-Thr-Cys)- Thr-Lys(cypate)-NH2' MOLECULAR LMAGING & CONTRAST AGENT DATABASE (MICAD) 2008, XP055162054 CAROLYN J. ANDERSON ET AL: "Copper-64 Radiopharmaceuticals for PET Imaging of Cancer: Advances in Preclinical and Clinical Research", CANCER BIOTHERAPY & RADIOPHARMACEUTICALS, vol. 24, no. 4, 1 August 2009 (2009-08-01) , pages 379-393, XP055164169, ISSN: 1084-9785, DOI: 10.1089/cbr.2009.0674 HANAOKA H. ET AL.: 'Evaluation of 64Cu-labeled DOTA-D-Phe1-Tyr3-octreotide (64Cu- DOTA- TOC) for imaging somatostatin receptor-expressing tumors' ANN. NUCL. MED. vol. 23, no. 6, 2009, pages 559 - 567, XP055147723

A. PFEIFER ET AL: "64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients", THE JOURNAL OF NUCLEAR MEDICINE, vol. 56, no. 6, 7 May 2015 (2015-05-07), pages 847-854, XP055414823, US ISSN: 0161-5505, DOI: 10.2967/jnumed.115.156539

HØJGAARD L.: 'Nuklearmedicin & kræftbehandling' DANSKE MEDICOTEKNISKE LANDSMØDE 1901-4465 vol. 27., September 2009, pages 1 - 93

R. Srirajaskanthan ET AL: "The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy", The Journal of Nuclear Medicine, vol. 51, no. 6, 19 May 2010 (2010-05-19), pages 875-882, XP055414643, US ISSN: 0161-5505, DOI: 10.2967/jnumed.109.066134

A. PFEIFER ET AL: "Clinical PET of Neuroendocrine Tumors Using 64Cu-DOTATATE: First-in-Humans Study", THE JOURNAL OF NUCLEAR MEDICINE, vol. 53, no. 8, 10 July 2012 (2012-07-10), pages 1207-1215, XP055163911, ISSN: 0161-5505, DOI: 10.2967/jnumed.111.101469


WEINER R E ET AL: "Radiolabeled peptides in the diagnosis and therapy of oncological diseases", APPLIED RADIATION AND ISOTOPES, ELSEVIER, OXFORD, GB, vol. 57, no. 5, 1 November 2002 (2002-11-01), pages 749-763, XP004381731, ISSN: 0969-8043, DOI: 10.1016/S0969-8043(02)00192-6

Jason S. Lewis ET AL: "Comparative Dosimetry of Copper-64 and Yttrium-90-Labeled Somatostatin Analogs in a Tumor-Bearing Rat Model", CANCER BIOTHERAPY& RADIOPHARMACEUTICALS Volume, 2000, pages 593-604, XP055164025, Retrieved from the Internet: URL:[http://online.liebertpub.com/doi/pdfpl us/10.1089/cbr.2000.15.593](http://online.liebertpub.com/doi/pdfpl/us/10.1089/cbr.2000.15.593) [retrieved on 2015-01-21]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelsen i formel I



Formel I

eller et farmasøytisk salt derav,

til anvendelse hos mennesker ved fremgangsmåte med *in vivo* diagnose av en nevroendokrintumor, hvori forbindelsen administreres med et måldose i området 150–250 MBq, diagnosen involverer en fremgangsmåte med røntgenavbildning, hvori cellene og vevene settes i kontakt med forbindelsen; og det gjøres en røntgenavbildning.

2. Forbindelse til anvendelse ifølge krav 1, hvori forbindelsen administreres med en måldose i området 191–210 MBq.
3. Forbindelse til anvendelse ifølge krav 1, hvori forbindelsen detekteres av et gamma-kamera, PET (positron emission tomography) og SPECT (single photon emission tomography), hvori forbindelsen administreres med en måldose i området 191–210 MBq.